Cytovia Therapeutics CEO Discusses SPAC Deal With Isleworth Healthcare

<p>The CEO of Cytovia Therapeutics Dr. Daniel Teper joins The Watchlist to discuss the company's focus on building a next-generation immuno-oncology therapeutics platform. The company was founded in 2018, and develops NK-cell and NK-engager antibody platforms to improve tumor-specific targeting in oncology patients. Dr. Teper also highlights the company's SPAC merger with Isleworth Healthcare. </p><p><br></p>